please find enclosed
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vivo Bio Tech Limited has subscribed to 86 lakh Convertible Equity Warrants issued by Virinchi Limited on a preferential basis. The warrants are priced at Rs. 28 each (Rs. 10 face value plus Rs. 18 premium), with Vivo Bio Tech paying 25% upfront, amounting to Rs. 6.02 crore. Each warrant can be converted into one fully paid-up equity share of Virinchi Limited upon paying the remaining Rs. 21 per warrant within the SEBI-prescribed period. The subscription follows shareholder approval at Virinchi's EGM on November 15, 2025, and in-principle approvals from BSE and NSE dated December 31, 2025.
This is a strategic investment by Vivo Bio Tech into Virinchi Limited, giving it the right to acquire a significant equity stake in a listed company upon conversion. Shareholders should view this as a capital deployment move — the Rs. 6.02 crore upfront commitment signals Vivo Bio Tech's confidence in Virinchi, and full conversion would make Vivo Bio Tech a notable shareholder of Virinchi Limited.